GYN Carcinosarcoma (also known as MMMT) is a rare uterine/ovarian cancer. The GCS Project started a fund dedicated to the research of this cancer, and ever since its inception in 2016, we’ve come a long way in short period of time.
Because of the rarity of this cancer, the research on this tumor has been limited. The cancer genome atlas (TCGA) only analyzed high-grade serous ovarian cancers. Other than the GCS Project, there is currently no research solely dedicated to finding a cure for GYN Carcinosarcoma (also known as GCS or MMMT). If you make a donation to the American Cancer Society, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance or other national research funds, NONE OF YOUR DONATION WILL GO TOWARDS FINDING A CURE FOR GYN CARCINOSARCOMA! If you want to make a difference towards scientific research specifically for GCS, the GCS fund will be the one to support.
For a more complete overview of the status of the research, please browse the GCS Research section to read more about why there is hope, all about the science, our research partners & specialists, the research progress, and more.
Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS). Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single… Read More »
Clinical trials are currently being offered at the University of Alabama at Birmingham. Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in… Read More »
Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC. A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab… Read More »